Recap's first peek into the biopharma dealmaking landscape since its acquisition in June by Thomson Reuters revealed the sector was on the move during the first half of 2013, with 368 licenses and joint ventures (JVs) compared to 265 during the first six months of 2012 – a 39 percent surge. (Thomson Reuters is the parent company of BioWorld Today.)